CIK 0001279704
- Non-accelerated filer
- Smaller reporting company
Cellectar Biosciences, Inc.
Sign in to watch- Ticker
- CLRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 043321804
- Phone
- +1 608-441-8120
- Business address
- 100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932
- Former names
- NOVELOS THERAPEUTICS, INC., COMMON HORIZONS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-25 | Elefant Dov Chief Financial Officer | Grant or award · Stock option (right to buy) | +422,000 | 422,000 | ||
| 2021-03-04 | Elefant Dov Chief Financial Officer | Grant or award · Stock option (right to buy) | +430,000 | 430,000 | ||
| 2020-12-28 | Elefant Dov Chief Financial Officer | Purchase | +7,407 | $1.35 | $10K | 11,755 |
| 2020-06-05 | Elefant Dov Chief Financial Officer | Purchase | +4,348 | $1.15 | $5K | 4,348 |
| 2020-06-05 | Elefant Dov Chief Financial Officer | Purchase · Series H Warrants | +2,174 | $0.01 | $22 | 2,174 |
| 2020-02-03 | Elefant Dov Chief Financial Officer | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2020-02-03 | Elefant Dov Chief Financial Officer | Grant or award | +10,000 | $2.71 | $27K | 10,000 |
| 2019-09-10 | Elefant Dov Chief Financial Officer | Grant or award · Stock Option (right to buy) | +90,000 | 90,000 |
Page 1 of 1 · 8 trades